Basic Information
Kerendia
Regulatory Information
EMEA/H/C/005200
Authorised
February 16, 2022
December 16, 2021
2
September 17, 2024
Company Information
Drug Classification
Additional Monitoring
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Kerendia is indicated for the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults.
Overview Summary
Kerendia is a medicine used to treat chronic kidney disease in adults with type 2 diabetes. It is used for patients with moderate or severe kidney damage who pass albumin (a type of protein) in their urine. Kerendia contains the active substance finerenone.